FDA Approves Targeted Treatment for Rare Duchenne Muscular Dystrophy Mutation ...Middle East

Washington, DC… Today, the U.S. Food and Drug Administration granted approval for Amondys 45 (casimersen) injection for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 45 skipping (Exons are pieces of DNA that provide information for making proteins in a person’s genome). The agency approved Amondys 45 based on an increase in dystrophin (a protein that helps keep muscle cells intact) production in skeletal muscle observed in patients treated with the therapy. This is the first FDA-approved targeted treatment for patients with this type of mutation. Approximately 8% of patients with DMD have a mutation that

Hence then, the article about fda approves targeted treatment for rare duchenne muscular dystrophy mutation was published today ( Friday 26/02/2021 - 02:01 AM ) and is available on Thepintree.net ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( FDA Approves Targeted Treatment for Rare Duchenne Muscular Dystrophy Mutation )

Also on site :

• Suspect in Mississippi synagogue fire laughed as he confessed to his dad, authorities say
• Fire crews and Hazmat teams responded to fire involving lithium ion batteries at Higuera Street facility
• No injuries reported after partial building collapse in the Bronx, officials say